病理完全缓解能否替代总生存用于胃食管腺癌新辅助试验
个体水平pCR与中位OS无显著相关(R²=0.006;p=0.210),试验水平治疗效应对pCR与OS的关联亦弱(R²=0.060;p=0.206)。替代性因亚组而异:食管腺癌强(R²=0.886;p<0.001),胃癌中等(R²=0.386;p=0.041),胃食管交界处肿瘤缺失。
要点
- 整体上pCR不能可靠替代OS,解读pCR结果需谨慎。
- 食管腺癌中pCR对OS替代性强(R²=0.886;p<0.001)。
- 胃癌中等(R²=0.386;p=0.041),GEJ肿瘤无替代性。
核心结论
- 在胃食管腺癌新辅助试验中,pCR整体上不是OS的可靠替代终点,解读pCR结果需谨慎。
- pCR对OS的替代性存在亚组差异,食管腺癌强、胃癌中等、胃食管交界处肿瘤缺失。
- 含放疗试验显示强替代性,单纯化疗试验未显示。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA和ReSEEM指南。
- 纳入报告pCR和OS的可切除远端食管、胃食管交界处或胃腺癌随机对照试验。
- 个体水平替代性通过pCR率与中位OS的相关性评估。
- 试验水平替代性通过pCR治疗效应(比值比)与OS治疗效应(风险比)的加权线性回归及决定系数(R²)评估。
主要发现
- 个体水平pCR与OS无显著相关(R²=0.006;p=0.210)。
- 试验水平pCR治疗效应仅解释少量OS效应变异(R²=0.060;p=0.206)。
- 食管腺癌亚组替代性强(R²=0.886;p<0.001)。
- 胃癌亚组替代性中等(R²=0.386;p=0.041)。
- 胃食管交界处肿瘤试验无替代性。
关键数值与推荐
- 个体水平替代性:R²=0.006;p=0.210。
- 试验水平替代性:R²=0.060;p=0.206。
- 食管腺癌:R²=0.886;p<0.001。
- 胃癌:R²=0.386;p=0.041。
- 胃食管交界处肿瘤:无替代性。
临床怎么用
- 不应仅凭pCR结果推断胃食管腺癌新辅助治疗的OS获益。
- 在食管腺癌中pCR可作为较强的OS替代指标参考。
- 胃癌中pCR替代性中等,需结合其他终点综合判断。
- 胃食管交界处肿瘤试验中pCR不宜作为OS替代终点。
- 未来免疫治疗试验中需重新评估pCR的替代性。
局限性
- 多数试验评估细胞毒化疗或放化疗,免疫治疗数据有限。
- 替代性分析基于试验水平聚合数据,非个体患者数据。
- 亚组分析样本量不一,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pathologic complete response (pCR) is frequently used as a surrogate endpoint in neoadjuvant gastroesophageal adenocarcinoma (GEA) trials, yet its validity in predicting overall survival (OS) remains uncertain. METHODS: This systematic review and meta-analysis, follows PRISMA and ReSEEM guidelines, and evaluates pCR as a surrogate for OS in randomized controlled trials (RCTs) of neoadjuvant therapy for GEA. Randomized trials enrolling patients with resectable distal esophageal, gastroesophageal junction (GEJ), or gastric adenocarcinoma were included if both pCR and OS were reported. Individual-level surrogacy was assessed by correlating pCR rates with median OS across trial arms; trial-level surrogacy was evaluated by correlating treatment effects on pCR (odds ratios) with treatment effects on OS (hazard ratios) using weighted linear regression and calculating the coefficient of determination (R²). RESULTS: Twenty-six RCTs including 7452 patients were analyzed. Overall, pCR showed no meaningful correlation with OS at the individual-level (R² = 0.006; p = 0.210), and treatment effects on pCR explained little of the variability in OS effects at the trial level (R² = 0.060; p = 0.206). Most trials evaluated cytotoxic chemotherapy or chemoradiotherapy. Surrogacy varied by subgroup, being strong for esophageal adenocarcinoma (R² = 0.886; p < 0.001), moderate for gastric cancer (R² = 0.386; p = 0.041), and absent for GEJ trials. Trials incorporating radiotherapy demonstrated strong surrogacy, whereas chemotherapy-only trials did not. CONCLUSIONS: The interpretation of pCR results in gastroesophageal adenocarcinoma trials requires caution. Surrogacy might need to be reassessed in the upcoming immunotherapy trials.
引用
- Leite LF, Noronha MM, Menezes S, et al. Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma? Eur J Cancer. 2026. PMID: 41759416. doi:10.1016/j.ejca.2026.116602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。